Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.
about
Treatment of five haemodynamically stable dogs with immune-mediated thrombocytopenia using mycophenolate mofetil as single agent.Circadian variation of cytotoxicity and genotoxicity induced by an immunosuppressive agent "Mycophenolate Mofetil" in rats.Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemiaSirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantationComparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.How I treat refractory acute GVHD.A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipientsA novel freeze-dried storage and preparation method for the determination of mycophenolic acid in plasma by high-performance liquid chromatography.Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation.Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantationHLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients.A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials NetworkMTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors.Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation.Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation.Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers.Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT).Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation.Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning.Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation.
P2860
Q33413713-8668CB34-6E4F-426F-9B7D-B4FF6BB44FBAQ33434301-431DBE81-EF4C-4588-B114-DEAE2203CD09Q34287623-A3FFE58E-E04E-4AC9-9CE8-DB5EEF996AD3Q35143457-C13338FD-DF70-4535-8F8A-CA374908A0F3Q35184589-1C7D67EE-B95D-44A9-B0D2-CDD55ED3B513Q35486258-94B4A1B9-E459-4B5B-BCD3-0234963D89FCQ35533371-B1855098-2991-4843-BFC9-3FD7287C6818Q35608022-033E6259-E51B-40DD-B5EF-66C6F95CFDF9Q35828633-E3C973F3-E7F3-40C3-B90F-BA55678889D4Q35843096-8F33EFE0-050B-44CF-A57C-EAE2B4130989Q36282140-D8E69E90-993A-46D3-B7D3-D867DDB16243Q36484688-21875E26-1366-4825-B92A-61609619E1C7Q36548358-7A68EDF7-FB6E-4990-BD51-DBA31CFFED99Q36623408-69E70546-D8E6-41B3-AF87-5B262EF8AD63Q36629233-4BB79029-FA48-4335-8DAB-AEE6F4938824Q36728151-9195C997-2831-4BD4-BEB8-C95F8D365DD8Q36777485-6C234513-CFF2-4F67-B36D-515506487923Q36980277-DDDA3D71-4BB0-4003-BD81-70EB4AFA3BF2Q37038889-672B793B-1CC9-48E2-B61C-4B74076F978DQ37078261-5C563E46-03F6-4644-87D9-375462DA4CE0Q37135382-777DCD16-7797-4A7C-9289-5DCF5B6BB5FAQ37206443-8DC46578-D961-4379-BBA5-0DEE0C8153DAQ38010596-14F60093-13F4-4383-82DA-F496F2C6CC31Q38262916-05D98E95-0C00-4146-919D-413CA31683A9Q38817096-3D87E882-F1AC-4D15-882A-5702E410CCB8Q40110923-EF5479D8-4940-43FF-8F33-B37006ECB1B8Q42149848-627078BD-43C0-4B23-ADAA-388495405DECQ43169783-93FB49D1-7018-4102-A614-461F05057446Q43283506-8BA3A9B7-D0BC-4B01-8926-DB721E2E8751Q43847839-662C2233-C8BB-41AB-B49D-8E55CB9F0D88Q46372141-86729411-4FBF-47FB-8DDD-50F5FFC9F106Q46504849-60194E9F-EAC7-4E6B-AD84-E358A3192615Q46736449-41BF7A9E-BC29-4338-8D64-C34684EE340BQ46847080-8B83604F-B61E-4615-918B-A536108609BFQ50686421-0A4EA105-762E-4851-B626-40307CD82D9BQ50703377-0B3FD582-829C-4D90-ADB1-526774ABFA39
P2860
Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacodynamics of mycophenol ...... opoietic cell transplantation.
@ast
Pharmacodynamics of mycophenol ...... opoietic cell transplantation.
@en
type
label
Pharmacodynamics of mycophenol ...... opoietic cell transplantation.
@ast
Pharmacodynamics of mycophenol ...... opoietic cell transplantation.
@en
prefLabel
Pharmacodynamics of mycophenol ...... opoietic cell transplantation.
@ast
Pharmacodynamics of mycophenol ...... opoietic cell transplantation.
@en
P2093
P2860
P1433
P1476
Pharmacodynamics of mycophenol ...... opoietic cell transplantation.
@en
P2093
George E Georges
Jeannine S McCune
John T Slattery
Luisa Giaccone
Michael B Maris
Richard A Nash
Scott Cole
Theodore A Gooley
P2860
P304
P356
10.1182/BLOOD-2005-06-2217
P407
P577
2005-09-06T00:00:00Z